AGIO stock information

Sector:

Healthcare

Description:

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharmaceuticals, Inc. website

Current Price

$26.05

RSI

57.67

Market Capitalization:

1.6B

Beta:

1.437

Volume:

392,434

Analyst Target Price:

$ 54.29

Economiic Fair Price:

Earnings DateNovember 03, 2022

Report DateNovember 03, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash122.4M

Debt88.9M

EPS26.55

Profit MarginN/A

Revenue Per Share TTM3.165

Return On Equity TTM-0.421

2020 Revenue

$ 203.2M

72.33 %

2019 Revenue

$ 117.9M

24.92 %

2018 Revenue

$ 94.4M

119.45 %

2017 Revenue

$ 43M

-38.46 %

2016 Revenue

$ 69.9M

2021 Free Cash Flow

$ -413.1M

-35.13 %

2020 Free Cash Flow

$ -305.7M

20.15 %

2019 Free Cash Flow

$ -382.8M

-22.92 %

2018 Free Cash Flow

$ -311.4M

-7.43 %

2017 Free Cash Flow

$ -289.9M

-1111.83 %

2016 Free Cash Flow

$ 28.6M

2020 Pre Tax Income

$ -327.4M

20.44 %

2019 Pre Tax Income

$ -411.5M

-18.91 %

2018 Pre Tax Income

$ -346M

-9.97 %

2017 Pre Tax Income

$ -314.7M

-58.55 %

2016 Pre Tax Income

$ -198.5M

Agios Pharmaceuticals, Inc.(AGIO)